Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> MutationsLecia V. Sequist, Martin Schüler, James Chih‐Hsin Yang et al.|Journal of Clinical Oncology|2013Cited by 3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Ramaswamy Govindan, Bob T. Li et al.|New England Journal of Medicine|2021Cited by 1.8k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung CancerYi‐Long Wu, Roy S. Herbst, Masahiro Tsuboi et al.|New England Journal of Medicine|2020Cited by 1.7k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih‐Hsin Yang, Lecia V. Sequist, Martin Schüler et al.|The Lancet Oncology|2015Cited by 1.6k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung CancerHeather A. Wakelee, Jonathan Spicer, Moïshe Liberman et al.|New England Journal of Medicine|2023Cited by 1k